Development and Cancer Program

西蒙斯综合癌症中心（SCCC）的发展和癌症（DC）计划是一个 由约书亚门德尔，医学博士，博士和斯蒂芬Skapek，医学博士共同领导的多学科计划。DC计划 包括来自UT西南部18个部门和中心的41名基础，计算和医生科学家 医疗中心（UTSW）。DC计划在SCCC计划中是独一无二的，因为其成员调查 在发育和进化上保守的过程是癌细胞生长，分裂， 和差异化。华盛顿特区的研究人员还研究器官和生物体的生长和发育过程 在人类癌症中脱轨。DC计划成员追求四个主要目标，以涵盖在 发育和癌症生物学接口：（1）干细胞生物学和再生的系统分析，（2） 探索基因表达和细胞命运，（3）研究细胞分化和器官发生，（4）分析 细胞-细胞和细胞-基质相互作用。DC项目负责人促进利用 来自SCCC和癌症中心支持补助金（CCSG）的资源，以提供一个研究环境， 促进实验室研究人员与翻译和临床研究人员之间的科学互动 研究人员因此，DC计划成员充分参与了肾脏和肝脏孢子项目，NCI 和CPRIT多研究者研究奖，并探索具有临床翻译潜力的主题。 这些努力中的许多已经开始接触到癌症患者，包括那些患有肺癌和肝癌以及其他癌症的患者。 在SCCC集水区尤其普遍的恶性肿瘤。直接同行审议供资共计 DC计划为1650万美元，其中29%来自NCI。这意味着同行评审资金增加了450万美元 与2014年的数据相比，这些数据经过调整以符合新的NCI指南。自2014年以来，DC计划 成员撰写了552份出版物：16%为方案内工作，47%为方案间工作 合作，30%的期刊影响因子>10。DC计划成员受益于使用 所有六个癌症中心共享资源，特别是活细胞成像，小动物成像和组织 管理为了促进合作，DC计划举办大型年度务虚会，领导相关的校园 研讨会系列，并组织以主题为重点的研究务虚会。此外，DC计划成员还收到了 在上一个赠款周期，150万美元的试点项目资金;这些资金有助于促进合作， 在发展和癌症生物学接口的研究。该计划是高度投资于解开 癌症生物学的基本要素，最终可以改善为患者提供的护理 得了癌症

The Development and Cancer (DC) Program at Simmons Comprehensive Cancer Center (SCCC) is a multidisciplinary program co-led by Joshua Mendell, MD, PhD, and Stephen Skapek, MD. The DC Program includes 41 basic, computational, and physician scientists from 18 departments and centers at UT Southwestern Medical Center (UTSW). The DC Program is unique among SCCC programs in that its members investigate the developmentally and evolutionarily conserved processes that are fundamental to cancer cell growth, division, and differentiation. DC investigators also study the organ and organism growth and developmental processes that are derailed in human cancer. DC Program members pursue four major aims to cover the diversity at the developmental and cancer biology interface: (1) Systematic analyses of stem cell biology and regeneration, (2) Exploring gene expression and cell fate, (3) Studies of cell differentiation and organogenesis, and (4) Analyzing cell–cell and cell–stroma interactions. DC Program Leaders promote utilization of the complete spectrum of resources from SCCC and the Cancer Center Support Grant (CCSG) to provide a research environment that stimulates scientific interactions between laboratory-based investigators and translational and clinical researchers. As a result, DC Program members have fully participated in Kidney and Liver SPORE projects, NCI and CPRIT multi-investigator research awards, and exploration of topics with high potential for clinical translation. Many of these efforts are beginning to reach cancer patients, including those with lung and liver cancer and other malignancies that are particularly prevalent in the SCCC catchment area. Total direct peer-reviewed funding to the DC Program is $16.5M, with 29% from NCI. This represents an increase of $4.5M in peer-reviewed funding compared with 2014 data, which were adjusted to conform to new NCI guidelines. Since 2014, DC Program members have authored 552 publications: 16% represent intraprogrammatic work, 47% are interprogrammatic collaborations, and 30% are in journals with an impact factor >10. DC Program members benefit from the use of all six of the Cancer Center Shared Resources, especially Live Cell Imaging, Small Animal Imaging, and Tissue Management. To foster collaborations, the DC Program holds a large annual retreat, leads relevant campuswide seminar series, and organizes theme-focused research retreats. In addition, DC Program members received $1.5M in pilot project funding during the last grant cycle; those funds have helped to catalyze collaborations and research at the development and cancer biology interface. The program is highly invested in unraveling the fundamental elements of cancer biology in a manner that can ultimately improve the care provided to patients with cancer.